Key Highlights
- Oxford Nanopore Technologies LSE:ONT was shown 3.31% higher on 22 September 2026.
- The latest move comes after a major Unified Patent Court preliminary injunction against MGI Tech GmbH relating to its Cyclone sequencing systems.
- The injunction covers several European jurisdictions, including the UK, Germany, France and the Netherlands, and relates to two Oxford Nanopore patents.
- Oxford Nanopore's H1 2026 Revenue increased 10.5% to £116.7 million, while gross Margin improved by 400 basis points to 62.2%.
- Adjusted EBITDA loss narrowed sharply to £22.1 million from £48.3 million, supporting the company's target of progressing toward breakeven in FY2027.
- Clinical revenue increased 35.4%, while BioPharma revenue rose 25.0% in H1 2026.
- PromethION revenue increased 15.7% to £59.1 million, highlighting continued Demand for the company's higher-throughput sequencing platform.
Why Is Oxford Nanopore Technologies LSE:ONT in Focus Today?
Oxford Nanopore Technologies LSE:ONT is attracting renewed investor attention following a combination of improving financial performance, increasing adoption of its sequencing technology and a significant recent intellectual-property development.
The most immediate company-specific catalyst is the 16 September 2026 preliminary injunction involving MGI Tech GmbH. The Munich Local Division of the Unified Patent Court ordered MGI Tech to refrain from making, offering, selling, using, importing, storing or supplying certain Cyclone sequencing systems and related flow cells across several European jurisdictions.
The legal development is particularly relevant because intellectual property is central to Oxford Nanopore's competitive position. The company has built its technology around nanopore-based molecular sensing and has continued investing heavily in its sequencing platform.
At the same time, the company's H1 2026 financial performance showed a significant improvement in margins and operating losses, giving investors a second major reason to monitor the shares.
Why Did Oxford Nanopore Technologies LSE:ONT Rise 3.31% on 22 September 2026?
Oxford Nanopore Technologies LSE:ONT was shown 3.31% higher on 22 September 2026.
There is no separately identified new company announcement on 22 September that fully explains the day's increase. The latest major company-specific development remains the preliminary injunction against MGI announced on 16 September.
The shares had already experienced strong Volatility during September. Trading data shows gains of 5.89% on 17 September and 2.11% on 18 September, followed by a 1.26% decline on 21 September.
The latest 3.31% gain therefore comes within a broader period of elevated trading activity around Oxford Nanopore.
Investors are simultaneously weighing the potential importance of the patent ruling against the company's financial progress, sequencing demand and long-term path toward profitability.
What Does the MGI Patent Injunction Mean for Oxford Nanopore?
The preliminary injunction is one of the most important recent developments surrounding LSE:ONT.
The Unified Patent Court granted Oxford Nanopore provisional protection after the company argued that MGI's Cyclone sequencing systems infringed two of its patents, EP 2 422 198 and EP 2 715 343. The order applies to Denmark, France, Germany, the Netherlands, Liechtenstein, Switzerland, the UK and Ireland, with a specific limitation in Ireland.
The order is immediately enforceable, subject to the applicable legal process, and includes penalty payments for non-compliance.
Oxford Nanopore has indicated that it intends to pursue permanent injunctive relief. The permanent-injunction trial is currently scheduled for October 2027.
For investors, the significance is that the ruling potentially strengthens Oxford Nanopore's ability to protect its technology in important European markets. However, a preliminary injunction is not the same as a final judgment, so the longer-term legal outcome remains subject to further proceedings.
What Did Oxford Nanopore Report in H1 2026?
Oxford Nanopore reported £116.7 million of revenue for H1 2026, up 10.5% from £105.6 million a year earlier. Constant-currency growth was 12.3%.
Gross profit increased 18.2% to £72.6 million, while gross margin improved from 58.2% to 62.2%.
The improvement in profitability was even more pronounced. Adjusted EBITDA loss narrowed to £22.1 million from £48.3 million, representing a £26.2 million year-on-year improvement.
The company attributed the progress to higher Gross Profit and tighter cost control, with adjusted operating costs down 6.9% year on year.
This is important because Oxford Nanopore's long-term Investment narrative increasingly depends on demonstrating that revenue growth can eventually translate into sustainable profitability.
Could Clinical and BioPharma Growth Become More Important?
Clinical and BioPharma applications are becoming increasingly significant parts of Oxford Nanopore's revenue mix.
Clinical revenue increased 35.4% to £17.6 million during H1 2026, while BioPharma revenue increased 25.0% to £9.5 million. Industrial revenue grew 6.2%, while Research revenue increased 5.4%.
The Diversification matters because the company has historically had substantial exposure to research customers.
Expanding adoption in clinical and pharmaceutical applications could broaden the addressable market and create additional recurring demand for sequencing devices, flow cells, kits and related services.
Investors will therefore be watching whether the strong first-half growth in these categories continues through the second half.
Why Is PromethION Important for LSE:ONT?
PromethION remains one of the key growth areas within Oxford Nanopore's product portfolio.
Revenue from the PromethION range increased 15.7% to £59.1 million during H1 2026, driven largely by strong demand for the P2i platform.
The growth was supported by customer demand in EMEAI, including activity involving Sequence ME and UK Biobank.
The MinION product range also grew, with revenue increasing 4.3% to £28.8 million.
The combination suggests that demand is not restricted to one individual product family, although PromethION currently provides an important contribution to the company's growth profile.
Is Oxford Nanopore Moving Closer to Breakeven?
The company is targeting progress toward breakeven in FY2027, and the H1 2026 results provide evidence of movement in that direction.
The adjusted EBITDA loss fell from £48.3 million to £22.1 million, while gross margin expanded significantly. Operating-cost discipline also contributed to the improvement.
However, Oxford Nanopore remained loss-making in H1, reporting a loss for the period of £48.0 million.
Cash, cash equivalents and other liquid investments stood at £234.5 million at 30 June 2026, down from £302.8 million at the end of 2025.
The next stage is therefore about maintaining revenue growth while continuing to reduce the operating loss.
What Should Investors Watch Next for LSE:ONT?
Investors will be watching second-half revenue growth, gross margins, adjusted EBITDA, cash usage and the pace of customer adoption.
The legal proceedings involving MGI will remain another major area of interest, particularly any developments concerning the injunction, potential appeals and the eventual permanent-injunction proceedings.
The company is also implementing a more focused strategy under CEO Francis Van Parys, concentrating resources on selected opportunities across BioPharma, Clinical and Research markets.
The next financial update will be particularly important for determining whether the improved first-half margin and EBITDA trends are continuing.
What Is the Main Oxford Nanopore Technologies LSE:ONT Stock Story on 22 September 2026?
The 3.31% rise in Oxford Nanopore Technologies LSE:ONT on 22 September 2026 comes as investors assess two interconnected themes: technology and intellectual-property strength alongside improving financial performance.
The MGI preliminary injunction provides an important development in Oxford Nanopore's effort to protect its patented sequencing technology, while the H1 results showed 10.5% revenue growth, a 400-basis-point gross-margin improvement and a substantial reduction in adjusted EBITDA losses.
The next phase of the stock story will centre on whether Oxford Nanopore can sustain its commercial growth, expand adoption in Clinical and BioPharma markets, protect its intellectual property and continue moving toward its FY2027 breakeven objective.
Top of Form
Bottom of Form






Please wait processing your request...